LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma.

Abstract:

:Immunotherapy with immune checkpoint molecule-specific monoclonal antibody have obtained encouraging results from preclinical studies and clinical trials, which promoted us to explore whether this kind of immunotherapy could be applicable to head and neck squamous cell carcinoma (HNSCC). Lymphocyte activation gene-3 (LAG-3) is an immune checkpoint control protein that negatively regulates T cells and immune response. Here, using the human tissue samples, we report these findings that LAG-3 is overexpressed on tumor-infiltrating lymphocytes (TILs; p < 0.001) and its overexpression correlates with the high pathological grades, lager tumor size and positive lymph node status in human primary HNSCC. Survival analysis identifies LAG-3 as a prognostic factor independent of tumor size and pathological grades for primary HNSCC patients with negative lymph node status (p = 0.014). Study in immunocompetent genetically defined HNSCC mouse model reports that LAG-3 is upregulated on CD4+ T cells, CD8+ T cells and CD4+Foxp3+ regulatory T cells (Tregs). In vivo study, administration of LAG-3-specific antibody retards tumor growth in a way associated with enhanced systemic antitumor response by potentiating the antitumor response of CD8+ T cells and decreasing the population of immunosuppressive cells. Taken together, our results offer a preclinical proof supporting the immunomodulatory effects of LAG-3 and suggest a potential therapeutic target of immunotherapy for HNSCC.

journal_name

Oncoimmunology

journal_title

Oncoimmunology

authors

Deng WW,Mao L,Yu GT,Bu LL,Ma SR,Liu B,Gutkind JS,Kulkarni AB,Zhang WF,Sun ZJ

doi

10.1080/2162402X.2016.1239005

subject

Has Abstract

pub_date

2016-10-07 00:00:00

pages

e1239005

issue

11

eissn

2162-4011

issn

2162-402X

pii

1239005

journal_volume

5

pub_type

杂志文章
  • Recent advances and new opportunities for targeting human dendritic cells in situ.

    abstract::Targeting antigens directly to dendritic cells (DCs) in situ has emerged as a promising strategy to potentiate immunity. A recent clinical trial of antibody-mediated targeting of tumor antigen NY-ESO1 to the DC receptor DEC-205 demonstrated an induction of strong cellular and humoral responses. Recent studies with DC-...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/21624011.2014.954832

    authors: Dhodapkar MV,Dhodapkar KM

    更新日期:2014-08-03 00:00:00

  • Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.

    abstract::An expanding panel of monoclonal antibodies (mAbs) that specifically target malignant cells or intercept trophic factors delivered by the tumor stroma is now available for cancer therapy. These mAbs can exert direct antiproliferative/cytotoxic effects as they inhibit pro-survival signal transduction cascades or activa...

    journal_title:Oncoimmunology

    pub_type: 评审

    doi:10.4161/2162402X.2014.985940

    authors: Vacchelli E,Pol J,Bloy N,Eggermont A,Cremer I,Fridman WH,Galon J,Marabelle A,Kohrt H,Zitvogel L,Kroemer G,Galluzzi L

    更新日期:2015-02-03 00:00:00

  • A perspective on new immune adjuvant principles: Reprogramming inflammatory states to permit clearance of cancer cells and other age-associated cellular pathologies.

    abstract::Aging entails the accumulation of neoantigens comprised of aggregated, oxidized, mutated and misfolded biomolecules, including advanced-glycation end projects (AGEs). There is evidence that the immune system can recognize and clear cells fouled by these molecular debris, which contribute to the emergence of cancer and...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.21358

    authors: Prendergast GC,Metz R

    更新日期:2012-09-01 00:00:00

  • Deubiquitinases A20 and CYLD modulate costimulatory signaling via CD137 (4-1BB).

    abstract::TRAF2 dependent K63-polyubiquitinations have been recently shown to connect CD137 (4-1BB) stimulation to NF-κB activation. In a search of deubiquitinase enzymes (DUBs) that could regulate such a signaling route, A20 and CYLD were found to coimmunoprecipitate with CD137 and TRAF2 complexes. Indeed, overexpression of A2...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2017.1368605

    authors: Azpilikueta A,Bolaños E,Lang V,Labiano S,Aznar MA,Etxeberria I,Teijeira A,Rodriguez-Ruiz ME,Perez-Gracia JL,Jure-Kunkel M,Zapata JM,Rodriguez MS,Melero I

    更新日期:2017-09-21 00:00:00

  • Egfl7 promotes tumor escape from immunity.

    abstract::Egfl7 is an endothelial-specific gene which expression is deregulated in human cancers. We showed that Egfl7 promotes tumor escape from immunity by downregulating the expression of leukocyte adhesion molecules in endothelial cells, thus repressing immune cell extravasation into tumors. ...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.18964

    authors: Pinte S,Soncin F

    更新日期:2012-05-01 00:00:00

  • Functional characterization of a STAT3-dependent dendritic cell-derived CD14+ cell population arising upon IL-10-driven maturation.

    abstract::Interleukin (IL)-10 is a major cancer-related immunosuppressive factor, exhibiting a unique ability to hamper the maturation of dendritic cells (DCs). We have previously reported that IL-10 induces the conversion of activated, migratory CD1a+ DCs found in the human skin to CD14+CD141+ macrophage-like cells. Here, as a...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.23837

    authors: Lindenberg JJ,van de Ven R,Lougheed SM,Zomer A,Santegoets SJ,Griffioen AW,Hooijberg E,van den Eertwegh AJ,Thijssen VL,Scheper RJ,Oosterhoff D,de Gruijl TD

    更新日期:2013-04-01 00:00:00

  • CD96 targeted antibodies need not block CD96-CD155 interactions to promote NK cell anti-metastatic activity.

    abstract::CD96 is a transmembrane glycoprotein Ig superfamily receptor, expressed on various T cell subsets and NK cells, that interacts with nectin and nectin-like proteins, including CD155/polio virus receptor (PVR). Here, we have compared three rat anti-mouse CD96 mAbs, including two that block CD96-CD155 (3.3 and 6A6) and o...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2018.1424677

    authors: Roman Aguilera A,Lutzky VP,Mittal D,Li XY,Stannard K,Takeda K,Bernhardt G,Teng MWL,Dougall WC,Smyth MJ

    更新日期:2018-02-01 00:00:00

  • Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition.

    abstract::High-risk endometrial cancer (EC) is an aggressive disease for which new therapeutic options are needed. Aims of this study were to validate the enhanced immune response in highly mutated ECs and to explore immune profiles in other EC subgroups. We evaluated immune infiltration in 116 high-risk ECs from the TransPORTE...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2016.1264565

    authors: Eggink FA,Van Gool IC,Leary A,Pollock PM,Crosbie EJ,Mileshkin L,Jordanova ES,Adam J,Freeman-Mills L,Church DN,Creutzberg CL,De Bruyn M,Nijman HW,Bosse T

    更新日期:2016-12-09 00:00:00

  • PD-L1 expression in metastatic neuroblastoma as an additional mechanism for limiting immune surveillance.

    abstract::The prognosis of high-risk neuroblastoma (NB) remains poor, although immunotherapies with anti-GD2 antibodies have been reported to provide some benefit. Immunotherapies can be associated with an IFNγ storm that induces in tumor cells the "adaptive immune resistance" characterized by the de-novo expression of Programm...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2015.1064578

    authors: Dondero A,Pastorino F,Della Chiesa M,Corrias MV,Morandi F,Pistoia V,Olive D,Bellora F,Locatelli F,Castellano A,Moretta L,Moretta A,Bottino C,Castriconi R

    更新日期:2015-07-15 00:00:00

  • IL-6 augments IL-4-induced polarization of primary human macrophages through synergy of STAT3, STAT6 and BATF transcription factors.

    abstract::Macrophages in the tumor microenvironment respond to complex cytokine signals. How these responses shape the phenotype of tumor-associated macrophages (TAMs) is incompletely understood. Here we explored how cytokines of the tumor milieu, interleukin (IL)-6 and IL-4, interact to influence target gene expression in prim...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2018.1494110

    authors: Gupta S,Jain A,Syed SN,Snodgrass RG,Pflüger-Müller B,Leisegang MS,Weigert A,Brandes RP,Ebersberger I,Brüne B,Namgaladze D

    更新日期:2018-07-30 00:00:00

  • Trial watch: dietary interventions for cancer therapy.

    abstract::Dietary interventions have a profound impact on whole body metabolism, including oncometabolism (the metabolic features allowing cancer cells to proliferate) and immunometabolism (the catabolic and anabolic reactions that regulate immune responses). Recent preclinical studies demonstrated that multiple dietary changes...

    journal_title:Oncoimmunology

    pub_type: 杂志文章,评审

    doi:10.1080/2162402X.2019.1591878

    authors: Lévesque S,Pol JG,Ferrere G,Galluzzi L,Zitvogel L,Kroemer G

    更新日期:2019-04-03 00:00:00

  • IL-33 increases ST2+ Tregs and promotes metastatic tumour growth in the lungs in an amphiregulin-dependent manner.

    abstract::Regulatory T cells (Tregs) facilitate primary and metastatic tumour growth through the suppression of anti-tumour immunity. Emerging evidence suggests a distinct role for Tregs in mediating tissue repair and barrier integrity in the lungs by IL-33 mediated production of the growth factor amphiregulin (AREG). Dependent...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2018.1527497

    authors: Halvorsen EC,Franks SE,Wadsworth BJ,Harbourne BT,Cederberg RA,Steer CA,Martinez-Gonzalez I,Calder J,Lockwood WW,Bennewith KL

    更新日期:2018-10-16 00:00:00

  • Chemokines and chemokine receptors required for optimal responses to anticancer chemotherapy.

    abstract::Depending on tumor type, stage and immunological contexture, the inhibition of chemokines or their receptors may yield positive or deleterious effects on disease progression. We have recently demonstrated in several murine models of anthracycline-based chemotherapy that the inhibition of chemokine (C-C motif) ligand 2...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.27663

    authors: Ma Y,Adjemian S,Galluzzi L,Zitvogel L,Kroemer G

    更新日期:2014-01-01 00:00:00

  • Peripheral trafficking of bone-marrow-derived stem cells in patients with different types of gastric neoplasms.

    abstract::Recently, there has been a growing interest in the importance of stem cells (SCs) in the development/progression of gastric neoplasms. In this study, we performed a comprehensive analysis of different populations of bone-marrow-derived stem cells (BMSCs) in patients with various types of gastric malignancies, includin...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2015.1099798

    authors: Błogowski W,Zuba-Surma E,Sałata D,Budkowska M,Dołęgowska B,Starzyńska T

    更新日期:2015-10-29 00:00:00

  • Flipping the script on macrophages in leiomyosarcoma.

    abstract::Macrophages promote the growth of leiomyosarcoma (LMS), a malignant soft-tissue tumor. CD47 on tumor cells binds to the macrophagic receptor signal regulatory protein α (SIRPα) and prevents phagocytosis. We showed that anti-CD47 monoclonal antibodies (mAbs) allow macrophages to engulf LMS cells and prevent tumor growt...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.20799

    authors: Edris B,Weiskopf K,Weissman IL,van de Rijn M

    更新日期:2012-10-01 00:00:00

  • Enhancing the clinical coverage and anticancer efficacy of immune checkpoint blockade through manipulation of the gut microbiota.

    abstract::Although anticancer therapy with immune checkpoint blockers has seen unprecedented success, it fails to control neoplasia in most patients and often causes immune-related adverse events (irAEs). Our recent research shows the immunostimulatory and antitumor effects of CTLA-4 blockade depend on distinct Bacteroides spec...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2015.1132137

    authors: Pitt JM,Vétizou M,Gomperts Boneca I,Lepage P,Chamaillard M,Zitvogel L

    更新日期:2016-02-18 00:00:00

  • PD-1 checkpoint blockade in advanced melanoma patients: NK cells, monocytic subsets and host PD-L1 expression as predictive biomarker candidates.

    abstract::Blockade of the PD-1 receptor has revolutionized the treatment of metastatic melanoma, with significant increases in overall survival (OS) and a dramatic improvement in patient quality of life. Despite the success of this approach, the number of benefitting patients is limited and there is a need for predictive biomar...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2020.1786888

    authors: Pico de Coaña Y,Wolodarski M,van der Haar Àvila I,Nakajima T,Rentouli S,Lundqvist A,Masucci G,Hansson J,Kiessling R

    更新日期:2020-08-28 00:00:00

  • HDAC inhibitors and their potential applications to glioblastoma therapy.

    abstract::Natural killer (NK) cells are integral components of the antitumor immune response. The downregulation of ligands for NK-cell stimulatory receptors represents a strategy whereby glioblastoma cells can evade NK-cell attacks. Histone deacetylase inhibitors can stimulate the (re)expression of these ligands, driving cytot...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.25219

    authors: Adamopoulou E,Naumann U

    更新日期:2013-08-01 00:00:00

  • The immune molecular landscape of the B7 and TNFR immunoregulatory ligand-receptor families in head and neck cancer: A comprehensive overview and the immunotherapeutic implications.

    abstract::The B7 family and tumor necrosis factor receptor (TNFR) superfamily play a vital role in the T-cell co-stimulatory and co-inhibitory pathways, regulating T-cell activation, tolerance, and exhaustion; therapeutic modulation of these pathways is translated into effective new cancer treatments. Better understanding of th...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2017.1288329

    authors: Chen YP,Zhang J,Wang YQ,Liu N,He QM,Yang XJ,Sun Y,Ma J

    更新日期:2017-02-16 00:00:00

  • Combined vaccination and immunostimulatory antibodies provides durable cure of murine melanoma and induces transcriptional changes associated with positive outcome in human melanoma patients.

    abstract::We have developed a recombinant adenovirus vaccine encoding dopachrome tautomerase (rHuAd5-hDCT) that produces robust DCT-specific immunity, but only provides modest suppression of murine melanoma. In the current study, an agonist antibody against 4-1BB was shown to enhance rHuAd5-hDCT efficacy and evoke tumor regress...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.19534

    authors: McGray AJ,Bernard D,Hallett R,Kelly R,Jha M,Gregory C,Bassett JD,Hassell JA,Pare G,Wan Y,Bramson JL

    更新日期:2012-07-01 00:00:00

  • Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma.

    abstract::We have made major advances in the treatment of melanoma through the use of targeted therapy and immune checkpoint blockade; however, clinicians are posed with therapeutic dilemmas regarding timing and sequence of therapy. There is a growing appreciation of the impact of antitumor immune responses to these therapies, ...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2015.1136044

    authors: Cooper ZA,Reuben A,Spencer CN,Prieto PA,Austin-Breneman JL,Jiang H,Haymaker C,Gopalakrishnan V,Tetzlaff MT,Frederick DT,Sullivan RJ,Amaria RN,Patel SP,Hwu P,Woodman SE,Glitza IC,Diab A,Vence LM,Rodriguez-Canales J,P

    更新日期:2016-02-02 00:00:00

  • Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells.

    abstract::Previous vaccination studies in patients with castration-resistant prostate cancer (CRPC) showed improved survival without prolongation of progression-free survival (PFS). This might be explained by enhanced efficacy of subsequent therapies because of heightened immune status. We therefore evaluated the efficacy of ch...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2015.1105431

    authors: van Dodewaard-de Jong JM,Santegoets SJ,van de Ven PM,Versluis J,Verheul HM,de Gruijl TD,Gerritsen WR,van den Eertwegh AJ

    更新日期:2015-12-21 00:00:00

  • Current Clinical Evidence and Potential Solutions to Increase Benefit of CAR T-Cell Therapy for Patients with Solid Tumors.

    abstract::Immunotherapy by chimeric antigen receptor (CAR)-modified T-cells has shown unprecedented clinical efficacy for hematological malignancies. Recently two CAR T-cell based therapeutics, Kymriah (Tisagenlecleucel) and Yescarta (Axicabtagene ciloleucel) were approved by the US Food and Drug Administration and by the Europ...

    journal_title:Oncoimmunology

    pub_type: 杂志文章,评审

    doi:10.1080/2162402X.2020.1777064

    authors: Alcantara M,Du Rusquec P,Romano E

    更新日期:2020-06-10 00:00:00

  • Targeting the C-terminus of galectin-9 induces mesothelioma apoptosis and M2 macrophage depletion.

    abstract::Galectin-9 has emerged as a promising biological target for cancer immunotherapy due to its role as a regulator of macrophage and T-cell differentiation. In addition, its expression in tumor cells modulates tumor cell adhesion, metastasis, and apoptosis. Malignant mesothelioma (MM) is an aggressive neoplasm of the mes...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2019.1601482

    authors: Bertino P,Premeaux TA,Fujita T,Haun BK,Marciel MP,Hoffmann FW,Garcia A,Yiang H,Pastorino S,Carbone M,Niki T,Berestecky J,Hoffmann PR,Ndhlovu LC

    更新日期:2019-04-17 00:00:00

  • Immunoglobulin genes implicated in glioma risk.

    abstract::Both genetic and environmental factors are thought to be causal in gliomagenesis. Several genes have been implicated in glioma development, but the putative role of a major immunity-related gene complex member, immunoglobulin heavy chain γ (IGHG) has not been evaluated. Prior observations that IGHG-encoded γ marker (G...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.28609

    authors: Pandey JP,Kaur N,Costa S,Amorim J,Nabico R,Linhares P,Vaz R,Viana-Pereira M,Reis RM

    更新日期:2014-05-23 00:00:00

  • Formyl peptide receptor 1 suppresses gastric cancer angiogenesis and growth by exploiting inflammation resolution pathways.

    abstract::Chronic inflammation can result from inadequate engagement of resolution mechanisms, mainly accomplished by specialized pro-resolving mediators (SPMs) arising from the metabolic activity of lipoxygenases (ALOX5/15) on ω-6 or ω-3 essential polyunsaturated fatty acids (PUFA). We previously demonstrated that formyl pepti...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2017.1293213

    authors: Prevete N,Liotti F,Illiano A,Amoresano A,Pucci P,de Paulis A,Melillo RM

    更新日期:2017-02-21 00:00:00

  • Longitudinal confocal microscopy imaging of solid tumor destruction following adoptive T cell transfer.

    abstract::A fluorescence-based, high-resolution imaging approach was used to visualize longitudinally the cellular events unfolding during T cell-mediated tumor destruction. The dynamic interplay of T cells, cancer cells, cancer antigen loss variants, and stromal cells-all color-coded in vivo-was analyzed in established, solid ...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.26677

    authors: Schietinger A,Arina A,Liu RB,Wells S,Huang J,Engels B,Bindokas V,Bartkowiak T,Lee D,Herrmann A,Piston DW,Pittet MJ,Lin PC,Zal T,Schreiber H

    更新日期:2013-11-01 00:00:00

  • Clonal expansion of renal cell carcinoma-infiltrating T lymphocytes.

    abstract::T lymphocytes can mediate the destruction of cancer cells by virtue of their ability to recognize tumor-derived antigenic peptides that are presented on the cell surface in complex with HLA molecules and expand. Thus, the presence of clonally expanded T cells within neoplastic lesions is an indication of ongoing HLA-r...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.26014

    authors: Sittig SP,Køllgaard T,Grønbæk K,Idorn M,Hennenlotter J,Stenzl A,Gouttefangeas C,Thor Straten P

    更新日期:2013-09-01 00:00:00

  • PD-L1 co-stimulation, ligand-induced TCR down-modulation and anti-tumor immunotherapy.

    abstract::PD-1 engagement on the surface of effector T cells strongly suppresses their cytotoxic function, which constitutes a major obstacle for T cell-mediated anti-tumor activities. Surprisingly, PD-1 is strongly upregulated in T cells, engaging its ligand PD-L1 during antigen presentation. However, our recent published data...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.1.1.17824

    authors: Karwacz K,Arce F,Bricogne C,Kochan G,Escors D

    更新日期:2012-01-01 00:00:00

  • Virotherapy-recruited PMN-MDSC infiltration of mesothelioma blocks antitumor CTL by IL-10-mediated dendritic cell suppression.

    abstract::Antitumor cytotoxic T lymphocytes (CTLs) are essential for immune surveillance, yet the blockade of eliciting such CTLs during oncolytic virotherapy remains incompletely understood. Here, we show that oncolysis of mesothelioma by modified vaccinia Tiantan (MVTT) induces damage-associated molecular patterns exposure. A...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2018.1518672

    authors: Tan Z,Liu L,Chiu MS,Cheung KW,Yan CW,Yu Z,Lee BK,Liu W,Man K,Chen Z

    更新日期:2018-10-16 00:00:00